353 related articles for article (PubMed ID: 36949946)
21. Involving stemness factors to improve CAR T-cell-based cancer immunotherapy.
Noraldeen SAM; Rasulova I; Lalitha R; Hussin F; Alsaab HO; Alawadi AH; Alsaalamy A; Sayyid NH; Alkhafaji AT; Mustafa YF; Shayan SK
Med Oncol; 2023 Oct; 40(11):313. PubMed ID: 37779152
[TBL] [Abstract][Full Text] [Related]
22. Engineering Next-Generation CAR-T Cells: Overcoming Tumor Hypoxia and Metabolism.
Gao TA; Chen YY
Annu Rev Chem Biomol Eng; 2022 Jun; 13():193-216. PubMed ID: 35700528
[TBL] [Abstract][Full Text] [Related]
23. CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge.
Guedan S; Alemany R
Front Immunol; 2018; 9():2460. PubMed ID: 30405639
[TBL] [Abstract][Full Text] [Related]
24. Nanotechnology-based chimeric antigen receptor T-cell therapy in treating solid tumor.
Zuo YH; Zhao XP; Fan XX
Pharmacol Res; 2022 Oct; 184():106454. PubMed ID: 36115525
[TBL] [Abstract][Full Text] [Related]
25. Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy.
Liu Z; Zhou Z; Dang Q; Xu H; Lv J; Li H; Han X
Theranostics; 2022; 12(14):6273-6290. PubMed ID: 36168626
[TBL] [Abstract][Full Text] [Related]
26. Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities.
Chen L; Chen F; Niu H; Li J; Pu Y; Yang C; Wang Y; Huang R; Li K; Lei Y; Huang Y
Front Immunol; 2022; 13():871661. PubMed ID: 35911706
[TBL] [Abstract][Full Text] [Related]
27. Preclinical Models in Chimeric Antigen Receptor-Engineered T-Cell Therapy.
Siegler EL; Wang P
Hum Gene Ther; 2018 May; 29(5):534-546. PubMed ID: 29390873
[TBL] [Abstract][Full Text] [Related]
28. CAR-T Plus Radiotherapy: A Promising Combination for Immunosuppressive Tumors.
Qin VM; Haynes NM; D'Souza C; Neeson PJ; Zhu JJ
Front Immunol; 2021; 12():813832. PubMed ID: 35095911
[TBL] [Abstract][Full Text] [Related]
29. Relapse after CAR-T cell therapy in B-cell malignancies: challenges and future approaches.
Gu T; Zhu M; Huang H; Hu Y
J Zhejiang Univ Sci B; 2022 Oct; 23(10):793-811. PubMed ID: 36226535
[TBL] [Abstract][Full Text] [Related]
30. The landscape of chimeric antigen receptor T cell therapy in breast cancer: Perspectives and outlook.
Zhang H; Zhu S; Deng W; Li R; Zhou H; Xiong H
Front Immunol; 2022; 13():887471. PubMed ID: 35935930
[TBL] [Abstract][Full Text] [Related]
31. Hurdles to breakthrough in CAR T cell therapy of solid tumors.
Marofi F; Achmad H; Bokov D; Abdelbasset WK; Alsadoon Z; Chupradit S; Suksatan W; Shariatzadeh S; Hasanpoor Z; Yazdanifar M; Shomali N; Khiavi FM
Stem Cell Res Ther; 2022 Apr; 13(1):140. PubMed ID: 35365241
[TBL] [Abstract][Full Text] [Related]
32. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
Kosti P; Maher J; Arnold JN
Front Immunol; 2018; 9():1104. PubMed ID: 29872437
[TBL] [Abstract][Full Text] [Related]
33. Tumor Microenvironment Immunosuppression: A Roadblock to CAR T-Cell Advancement in Solid Tumors.
Johnson A; Townsend M; O'Neill K
Cells; 2022 Nov; 11(22):. PubMed ID: 36429054
[TBL] [Abstract][Full Text] [Related]
34. Combining Oncolytic Viruses with Chimeric Antigen Receptor T Cell Therapy.
McGrath K; Dotti G
Hum Gene Ther; 2021 Feb; 32(3-4):150-157. PubMed ID: 33349123
[TBL] [Abstract][Full Text] [Related]
35. Remodeling of Tumor Microenvironment by Tumor-Targeting Nanozymes Enhances Immune Activation of CAR T Cells for Combination Therapy.
Zhu L; Liu J; Zhou G; Liu TM; Dai Y; Nie G; Zhao Q
Small; 2021 Oct; 17(43):e2102624. PubMed ID: 34378338
[TBL] [Abstract][Full Text] [Related]
36. Efficient combination of radiotherapy and CAR-T - A systematic review.
Szlasa W; Sztuder A; Kaczmar-Dybko A; Maciejczyk A; Dybko J
Biomed Pharmacother; 2024 May; 174():116532. PubMed ID: 38574625
[TBL] [Abstract][Full Text] [Related]
37. Challenges in the Treatment of Glioblastoma by Chimeric Antigen Receptor T-Cell Immunotherapy and Possible Solutions.
Zhang P; Zhang Y; Ji N
Front Immunol; 2022; 13():927132. PubMed ID: 35874698
[TBL] [Abstract][Full Text] [Related]
38. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy.
Pan K; Farrukh H; Chittepu VCSR; Xu H; Pan CX; Zhu Z
J Exp Clin Cancer Res; 2022 Mar; 41(1):119. PubMed ID: 35361234
[TBL] [Abstract][Full Text] [Related]
39. Prospects and challenges for use of CAR T cell therapies in solid tumors.
Ramakrishna S; Barsan V; Mackall C
Expert Opin Biol Ther; 2020 May; 20(5):503-516. PubMed ID: 32125191
[No Abstract] [Full Text] [Related]
40. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
Zhang E; Gu J; Xu H
Mol Cancer; 2018 Jan; 17(1):7. PubMed ID: 29329591
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
